pharma news today obesity drugs glp-1 today U.S. FDA | FDA issued its fastest approval for a novel drug (NME) since 2002, as part of the national priority voucher pilot program. ✔️ New What is the pipeline for
Description
Mller, T

This ensures proper dosing, follow-ups, and adjustments when needed
Experimental studies have also pointed to a direct ICP-lowering effect of GLP-1RAs

Obesity / chronic weight management is the fastest growing segment, driven by the escalation of world obesity and the growing body of evidence for the utility of GLP-1 therapies in weight loss
10.1016/j.kint.2020.08.037 [DOI] [PubMed] [Google Scholar] 28
